NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, version 7.2025 - Featured Updates to the NCCN Guidelines Guidelines


Authors: Riely, G. J.; Wood, D. E.; Aisner, D. L.; Loo, B. W. Jr; Axtell, A. L.; Bauman, J. R.; Bharat, A.; Chang, J. Y.; Desai, A.; Dilling, T. J.; Dowell, J.; Durm, G. A.; Gettinger, S.; Grotz, T. E.; Gubens, M. A.; Juloori, A.; Lackner, R. P.; Lanuti, M.; Levy, B.; Lin, J.; Lovly, C. M.; Maldonado, F.; Morgensztern, D.; Mullikin, T. C.; Ng, T.; Owen, D.; Owen, D. H.; Patel, S. P.; Patil, T.; Polanco, P. M.; Riess, J.; Mendez, A. L. R.; Shapiro, T. A.; Singh, A. P.; Stevenson, J.; Tam, A.; Tanvetyanon, T.; Yanagawa, J.; Yau, E.; Gregory, K.; Hang, L.
Title: NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, version 7.2025 - Featured Updates to the NCCN Guidelines
Abstract: <p>The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of NSCLC. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines, with a focus on systemic therapy options for the treatment of patients with nonmetastatic NSCLC and the corresponding molecular testing considerations.</p>
Keywords: survival; recurrence; surgery; therapy; phase-iii trial; preoperative chemotherapy; vinorelbine plus cisplatin
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 23
Issue: 9
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2025-09-01
Start Page: 354
End Page: 362
Language: English
ACCESSION: WOS:001571933800010
DOI: 10.6004/jnccn.2025.0043
PROVIDER: wos
PUBMED: 40930154
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gregory J Riely
    607 Riely
Related MSK Work